[DPhe7]-Bradykinin
Bradykinin is a peptide that exhibits natriuretic, antioxidative, vasodilatory, and pro-angiogenic activities. Bradykinin stimulates bradykinin receptors and increases PLC activity, decreasing ENaC open probability, inhibiting distal nephron Na+ transport, and inducing natriuresis. In vitro, bradykinin decreases H2O2-induced senescence, increases activity of superoxide dismutase (SOD), and suppresses DNA damage, ROS production, and NADPH oxidase activity. Additionally, bradykinin increases expression of VEGF and promotes tube formation in prostate cancer cells.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18830194
| Purity |
≥95% |
|---|---|
| Formula |
C54H75N15O11 |
| Formula Wt. |
1110.29 |
product targets : HSV inhibitors
Mamenko M, Zaika O, Pochynyuk O. Direct regulation of ENaC by bradykinin in the distal nephron. Implications for renal sodium handling. Curr Opin Nephrol Hypertens. 2014 Mar;23(2):122-9. PMID: 24378775.
Yu HS, Wang SW, Chang AC, et al. Bradykinin promotes vascular endothelial growth factor expression and increases angiogenesis in human prostate cancer cells. Biochem Pharmacol. 2014 Jan 15;87(2):243-53. PMID: 24225154.
Dong R, Xu X, Li G, et al. Bradykinin inhibits oxidative stress-induced cardiomyocytes senescence via regulating redox state. PLoS One. 2013 Oct 25;8(10):e77034. PMID: 24204728.
Feher A, Cassuto J, Szabo A, et al. Increased tissue angiotensin-converting enzyme activity impairs bradykinin-induced dilation of coronary arterioles in obesity. Circ J. 2013;77(7):1867-76. PMID: 23603844.
